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Abstract
Background: Overt bleeding associated with low dose aspirin (LDA) is well-recognized, little attention is given to
the possibility of association between LDA and occult bleeding, although this is known to occur in healthy
volunteers. LDA is used increasingly in primary and secondary prevention of a number of medical conditions, many
of which are common in older people, as is anemia. Anemia in older people is associated with adverse outcomes
including disability, morbidity and mortality. The purpose of this study was to review the evidence that LDA might
cause anemia without overt bleeding.
Methods: An extensive narrative review was carried out. Electronic searching (including database links) and
reference lists of reports were used to identify studies reporting on use of aspirin ≤325 mg/day and anemia or
change in hemoglobin (Hb) without overt bleeding. Data were extracted from reports of trials, adverse drug
reactions (ADRs) and prevalence studies of adults aged ≥18 years, published since 1980.
Results: There are few relevant data, with considerable heterogeneity among trial designs, duration, and patient
characteristics in studies of LDA. In five randomised trials (n = 5879) in (mostly secondary) prevention, the majority
of patients were men without peptic ulcer disease aged 50-70 years and no consistent association between LDA
and change in Hb was found. In two smaller studies (n = 609) of primary prevention in healthy patients aged ≥70
years, there was a small but statistically significant fall in Hb with LDA. Observational studies, and data from trials in
which use of LDA was not a primary focus of the study, were inconclusive.
Conclusions: It is not clear whether there is an association between LDA and anemia in the absence of overt
bleeding, but there may be an association between LDA and fall in Hb in (a subset of) older patients. The available
evidence has significant limitations, which are discussed; studies including more older patients, and publication of
individual patient data, would help clarify this important matter.
Background
Low dose aspirin (LDA) is taken by an increasing num-
ber of people for prophylaxis in a widening variety of
medical conditions, including cardio- and cerebrovascu-
lar disease, dementia, and some malignancies. Many of
these conditions are common, particularly in older peo-
ple, and changes in demographics (with increasing life
expectancy and higher numbers of older people) mean
that there is potential for many more older people to
take LDA. Improved chance of survival for patients with
some of these conditions (after myocardial infarction,
for instance) contribute to increased life expectancy, and
indeed, may result partly from the use of LDA as pro-
phylaxis. The place of LDA is not yet fully identified,
particularly in primary prophylaxis in some conditions.
Furthermore, evidence obtained from studies on
younger people may not be applicable to older patients.
Although there have been many studies reporting on
overt gastrointestinal bleeding as a primary or secondary
outcome of interest [1,2], little attention has been given
to the possibility that LDA use may be complicated by
occult bleeding, possibly leading to anemia. There is
some evidence from experimental studies that LDA is
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healthy young volunteers [3].
Anemia is common in older people [4,5]. It may be
asymptomatic, but it is associated with increases in mor-
tality [6-9], morbidity (in a number of conditions) [4],
falls [10,11] and disability [12-14], as well as deterioration
in cognitive function [15-17]. Even mildly low Hb levels
(above the WHO criteria for anemia, Hb < 130 g/L in
men and <120 g/L in women [18]) have been found to be
associated with significant decline in quality of life in
older people [19].
There are other implications beyond the wellbeing of
individuals, particularly for costs of health care for an
ageing population. Because of the importance of anemia
and the uncertainty as to whether taking LDA has a
clinically significant effect on Hb (other than in the con-
text of overt bleeding), we carried out a review to exam-
ine whether there is any evidence of an association
between use of LDA and anemia.
Methods
We searched for evidence from systematic reviews, ran-
domised trials, observational studies of clinical practice
and epidemiological data in several areas:
1. Evidence of changes in Hb during treatment with
LDA in randomized trials, where LDA was used as
either primary treatment or as a comparator drug.
In trials where LDA was used both alone and in
combination with another antiplatelet drug (or with
an anticoagulant), data were extracted from the trial
arm in which LDA alone was used.
2. Evidence from randomized trials in which change
in Hb or anemia was reported as an adverse event
(ADR) occurring in patients treated with LDA (or
evidence that no such ADR had occurred).
3. Evidence from prevalence studies, including data
on LDA prescribing and prevalence of anemia (and/
or Hb) in different clinical situations.
We considered data from studies on adults in which
LDA was used either in primary or secondary preven-
tion, with a maximum dose of 325 mg/day. Data on
overt/acute bleeding episodes were excluded. We noted
authors’ definitions of anemia where this differed from
the WHO criteria. We also noted data on co-morbidities
and exclusions from studies.
Several different search strategies were used to find
full publications of studies relating to these outcomes.
These were predominantly free-text searches of
PubMed, EMBASE (accessed through the Ovid inter-
face), and the Cochrane Library, to November 2009,
including, but not limited to, aspirin, acetylsalicylic, an
(a)emia, h(a)emoglobin, h(a)ematocrit, prophylaxis,
adverse. We also carried out searches using additional
search terms such as cardiovascular, dementia, cancer.
A specimen search strategy is shown (in Additional file
1: Specimen search strategy). The sensitivity of electro-
nic databases for observational studies is known not to
be high [20,21], so bibliographies of papers, reviews and
“linked articles” in PubMed were extensively searched
for references to clinical and other potentially relevant
studies.
Any study that might have contributed was obtained
in full and read. For inclusion, the only criterion was
that of full publication; abstracts or posters were not
accepted. Formal quality scoring of included studies was
not considered feasible because of the likely mix of
systematic reviews, randomised trials, and observational
studies. Because of the problems in searching for data
on events that were often not considered as primary,
secondary or even adverse event outcomes, and the
enormous number of reports that could potentially con-
tain relevant data, we did not feel able to call this review
systematic. We consider it to be an extensive narrative
review. There was no pooling of data; no statistical
methods were planned, and none used.
Results
1. Clinical trials
There were seven randomised trials (six double blind
and placebo controlled) in which LDA was used at
d o s e so f5 0m gt o3 2 4m gd a i l ya n dH bo rr e l a t e d
hematological data were reported as primary or second-
ary outcomes [22-28]. Study details and results are
shown in Additional file 2 (Additional file 2: Trial data:
LDA as either primary treatment or as comparator
drug). Relevant data were available from 6488 patients.
Trial duration varied between 12 weeks and six years
although the nature of some of the trials was such that
there were few data available from patients at longer
durations of treatment because of withdrawals.
The trials fell into two groups. In five studies of LDA
in (mostly secondary) prevention of cardio- and/or cere-
brovascular disease [22,23,25-27] the majority of the
5879 patients were men aged 50-70 years old, and mean
baseline Hb was between 133 and 151 g/L [25-27].
Reported co-morbidities were similar and of the sort
that might be expected (such as hypertension), and half
were current or ex-smokers. Peptic ulcer disease and
severe co-morbid illness were commonly excluded. In
two studies [22,23] falls in Hb or Hct after baseline
were reported in patients taking LDA and in those tak-
ing placebo. There was no significant difference between
results from the treatment and placebo arms in either
study. Mean Hb in both the LDA and placebo arms did
not change in the first year after baseline, but fell in the
second year of a large study [26,29,30]. Unfortunately,
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changes in mean Hb or Hct from baseline to one or two
years in each group, or of differences between the mean
Hb or Hct in the two groups at a particular time. How-
ever, the samples are large, and it is possible that the
fall in Hb seen in both groups over the second year
might be statistically significant even though it is small.
A significant rise in Hb at 3 months after baseline was
reported from a small study in which LDA was used as
a comparator drug (no placebo arm), with a similar
value at 4 years [27]. Very small rises in Hb (not statisti-
cally significant) were also reported in another study
[25,31], with no significant difference between results
from treatment and placebo arms; however, the magni-
tude of the standard errors suggest that the underlying
distributions of the data may have been skewed.
In two smaller studies [24,28], enteric coated (ec)
aspirin 100 mg was prescribed for primary prevention of
cardio- or cerebrovascular disease in 609 patients aged
70 or older, with similar numbers of men and women.
Patients included in these two studies had similar mean
baseline Hb (142 and 140 g/L respectively), were in
good general health, and 24% [24] and 44% [28] were
current or ex-smokers. In both of these studies there
was a statistically significant fall in Hb at one year com-
pared with baseline in the LDA arms of the trials, but
not in the placebo groups; there were also statistically
significant differences in Hb between LDA and placebo
groups at one year in both studies. One study [24]
reported the percentage of patients in whom Hb fell by
10 g/L or more, and here too there was a statistically
significant difference between the LDA and placebo
groups, although there was no significant difference
between the two groups with respect to the percentage
of patients with any fall in Hb over one year.
2. Anemia or change in Hb reported as an ADR
Relevant adverse event data (fall in Hb or Hct, or ane-
mia) were available from several studies [32-38] in
which LDA at doses of 75-325 mg daily was used. There
was considerable heterogeneity among the study designs.
The timing of adverse events was not reported and
where anemia was reported, the criteria for diagnosis
w e r en o ts t a t e de x p l i c i t l y .S t udy details and results are
shown in Additional file 3 (Additional file 3: ADR data:
LDA as either primary treatment or as comparator
drug).
The prevalence of relevant adverse events ranged
between 0% and 4.4%. In one study [37] anemia (defined
using a probable criterion of only Hb <90 g/L [39])
occurred less frequently in patients taking LDA at a
dose of less than 162 mg daily than in those taking LDA
162-325 mg daily, 70 patients (3.0%) versus 97 patients
(4.4%) (p = 0.011).
3. Prevalence studies
We found data on prevalence of LDA prescribing and
anemia (or Hb levels) in three studies in community set-
tings [40-42], noted as patient characteristics in three
studies of treatment of cardiovascular disease in older
patients [43-45], and in four studies in secondary care in
patients considered for investigation of anemia [46-49].
The majority of the data were from older patients.
Study details and results are shown in Additional file 4
(Additional file 4: Prevalence data: LDA use in various
settings).
Prevalence studies- community settings
T h ep r e v a l e n c eo fL D Ap r e s c r i p t i o ni nap r i m a r yc a r e
population and the mean change in Hb over time (in
the absence of overt bleeding) were observed [40].
There was a statistically significant fall from baseline in
mean Hb in the men and a rise (not statistically signifi-
cant) in mean Hb in the women over a mean period of
25 months. Related data from small subgroups of
patients were also reported, including the observation
that mean Hb fell by over 10% in 15% of older patients
taking LDA. Cross sectional data from two cohort stu-
dies [41,42] of similar characteristics showed no statisti-
cally significant independent effect of LDA on Hb [41]
and a slightly higher Hb (and lower prevalence of ane-
mia as defined by WHO criteria) in LDA users than in
non-users [42].
Prevalence studies - data from patient characteristics in
three studies of treatment of cardiovascular disease
Data on aspirin use (probably LDA) and Hb are reported
from sub-analyses in studies on the outcomes of treat-
ments of chronic stable angina [45] and chronic heart
failure (CHF) [43]. One study found no difference in the
prevalence of aspirin (probably LDA) prescription in ane-
mic and non-anemic patients, anemia being defined by
WHO criteria [45], but in another study [43] mean Hb
was slightly lower in aspirin users compared with non-
users (the difference was statistically significant).
The relationship between prior aspirin use and out-
comes was examined in a very large study of almost
119,000 patients admitted to hospital with acute myo-
cardial infarction [44]. Aspirin use before admission was
associated with a small but statistically significant higher
mean Hb; dose and duration of aspirin use were not
known, but it was likely to have been LDA for most
patients.
Prevalence studies- data from secondary care
Several studies of patients referred to secondary care for
assessment of iron deficiency anemia (IDA) have reported
aspirin use as a patient characteristic [46-48]; unfortu-
nately none of these studies had assessment of a relation-
ship between aspirin consumption and Hb/iron status as a
primary outcome. Aspirin was taken by 25-29% of patients
who had no symptoms that suggested a cause for IDA
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were taking aspirin, but in a subgroup (53%) in which no
cause of IDA was found, 41% were taking aspirin, while
the prevalence of regular aspirin prescription among
patients of similar age in the same catchment area as
those referred for investigation of IDA was 11% [46].
Although these are very small studies with limited infor-
mation reported on indications for aspirin prescription,
aspirin dosage, duration of consumption, co-morbidities
and other possibly relevant medication (such as NSAIDs),
it is likely that the patients in all these studies took aspirin
for prophylaxis rather than as analgesics.
In a more recent prospective study [49] of investiga-
tion of IDA in patients admitted as inpatients to general
medical services (apart from admissions for acute GI
bleeds), mean Hb and prevalence of LDA prescription
were reported with other related data. There was no
information on prevalence of LDA prescribing in the
catchment area from which the hospital received its
acute admissions.
Discussion
The most striking observation is that there is so little
relevant information on possible covert effects on Hb
with such a commonly prescribed drug as aspirin,
despite its well-known propensity to cause significant
overt gastrointestinal bleeds in some patients. We are
aware of the difficulties in identifying all relevant data,
(particularly from studies other than trials of LDA in
which change in Hb was a primary outcome) but, given
the small amount of such trial data available, feel that it
is appropriate to present the additional data that we
have found, despite their potential limitations. The rele-
v a n ta v a i l a b l ed a t a( f r o maw i d er a n g eo ft y p e so fs t u d y
and outcomes) show no consistent association between
LDA and anemia. While some studies indicated that Hb
levels were reduced with LDA, others showed no
change, or even suggested a higher Hb level. Anemia,
however defined, was not consistently associated with
a s p i r i nu s e .W eb e l i e v et h a tt h e r ea r ean u m b e ro ff a c -
tors relevant both to the lack of data, and to the inter-
pretation of what data are available.
The limited trial evidence shows that there is either
no effect of LDA on mean Hb, or a very small effect but
with considerable variability compared to the effect size.
However the trial data should be interpreted with cau-
tion; there is considerable clinical heterogeneity among
the studies (indication for LDA, dose of LDA, age of
participants, duration of trial, data collected, exclusions,
and co-morbidities), making it difficult to draw any firm
conclusions on the effect of LDA on Hb in the absence
of overt bleeding. The majority of trial data comes from
men aged 50-70 years with cardio- and/or cerebrovascu-
lar disease, including a high proportion of smokers.
There are very small amounts of trial data on LDA and
Hb in primary prevention in healthy older patients, and
it is not reassuring to find that the trial evidence avail-
able suggests that in these patients LDA is associated
with a fall in Hb, at least when taken for one year
[24,28]. We lack information on other groups, in parti-
cular on secondary prevention in older people, whether
fit or frail. Conditions where LDA prescription may be
appropriate are common in older people and many clin-
icians will recognize the common scenario of having to
decide on prescribing LDA for secondary prevention in
a mildly anemic elderly patient.
Exclusions, withdrawals from trials, and compliance
issues may have had an important impact on the results.
The trial data largely precede the widespread use of pro-
ton pump inhibitors (PPIs) or Helicobacter pylori eradi-
cation therapy; patients with a history of peptic ulcer
were excluded from trials of LDA, and the results of
these trials may not be readily applicable to patients who
take PPI drugs with LDA. There is little formal reporting
of reasons for withdrawal from these trials (except where
withdrawal occurred because a pre-determined end-point
was reached, such as a cardio- or cerebrovascular event
in trials where LDA was used for secondary prevention),
but aspirin intolerance associated with upper gastro-
intestinal symptoms is common. If such symptoms are
associated in some patients with occult bleeding suffi-
cient to cause a fall in Hb, there is potential for bias in
trial results if affected participants withdraw from a trial.
There might be similar bias with (lack of) compliance
with LDA [50]. A large Scottish study of patients (mostly
aged 60 or more) showed that compliance at a year was
less than 50% [51].
Many patients taking LDA have co-morbidities which
themselves may be relevant to the development of ane-
mia (chronic heart failure would be one example). Such
co-morbidities, and drugs used to treat them, make it
more difficult to identify effects on Hb specific to LDA.
In particular, not all studies indicated whether patients
taking NSAIDs were excluded, and possible effects of
even short term or intermittent NSAID use in a longer-
term study are difficult to evaluate.
In studies where Hb is recorded during acute illness,
the timing of blood sampling can be critical because Hb
can vary during acute illness [27,52]. This phenomenon
is relevant to trials on LDA in secondary prevention
where baseline Hb data were used, and similarly in trials
on other drugs or interventions where data on Hb and
prevalence of LDA use were reported as baseline charac-
teristics. Moreover, there are also potentially significant
diurnal [53] and day-to-day [54] changes in Hb and Hct.
Much used for over a century, in the last twenty years
aspirin has been prescribed for many new indications, and
at progressively smaller doses. Because of this history, its
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temporary criteria necessary for licensing a new drug. Per-
haps familiarity has bred complacency over associated
ADRs. ADRs are difficult to study, are often incompletely
reported, and reports of ADRs may not be readily found
in databases [55]. It is particularly hard to identify ADRs
where the event rate is low and the background rate is not
known, and even harder where the ADRs are not clinically
obvious. Acute gastrointestinal bleeds severe enough to
require hospital admission are, of course, obvious (and
relatively easy to count). A gradual fall in Hb or recurrent
small bleeds over a long period might not be obvious to
the patient or to health professionals, as the effects can be
subtle and non-specific (such as increased tiredness) or
indirect (for instance worse prognosis in CHF). Develop-
ment of anemia may well be, by nature, insidious and diffi-
cult to identify without serial blood sampling. And LDA
might affect Hb other than by causing bleeding from the
GI tract (for instance, it has been suggested that LDA
might act as an anti-inflammatory drug, tending to
increase Hb). Individuals might well differ in their suscept-
ibility to such effects. A clinically significant effect in a
small subgroup of patients may not be readily apparent
from inspection of mean values for the group as a whole.
If, say, LDA caused occult bleeding in a subgroup of 5% of
patients such that their Hb fell by 20 g/L and the remain-
ing 95% had no change in Hb, the mean change for the
group as a whole would only be 1 g/L.
Individual patient data could be particularly helpful to
identify patterns of changes in Hb; some patients might
have small amounts of occult gastrointestinal bleeding
which occurs from time to time, or they might have
persistent bleeding. Sequential measurement of Hb in
individuals would be necessary to find out, but appropri-
ate controls would be required as Hb tends to fall in
older age [56-59]. (Increasing knowledge of the pro-
cesses underlying the development of anemia in older
people [60,61] may well be of significance for under-
standing possible effects on Hb due to LDA.) If indeed
LDA is significantly associated with falls in Hb, it would
be very useful to identify characteristics that make
patients potentially more vulnerable - frailty and specific
co-morbidities are obvious candidates. The current posi-
tion of LDA in secondary prevention in cardio- and cer-
ebrovascular disease mean that it is unlikely that in
future, trials will be run with LDA compared to placebo,
but there might be opportunities in studies in primary
prevention (as in the ASPREE trial in progress [28]) or
where LDA is used for other conditions.
Conclusions
It is not clear whether there is a clinically significant
effect of LDA on Hb in adults in the absence of overt
bleeding, but the limited evidence available at present
cannot rule this out and suggests that it may be a pro-
blem in older people, or a subset of them. This is an
important issue because of the expanding use of LDA
by older people and the associations between anemia
and impaired function and quality of life, morbidity and
mortality.
Note added in proof
Since the revised, peer reviewed version of this paper
was submitted, another observational study has been
published (Al-Azzam SI, AlMahasneh F, Mhaidat N,
Alzoubi KH, Khader YS: Prophylactic use of aspirin
does not induce anaemia among adults. J Clin Pharm
Ther 2010, 35:415-419.) The results of this study are
consistent with those of some other observational stu-
dies which are included in the review, and do not affect
our conclusions.
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used in a randomised trial
Additional file 3: ADR data: LDA as either primary treatment or as
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